These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35821280)

  • 1. Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium.
    Starcevic Manning M; Hassanein M; Partridge MA; Jawa V; Mora J; Ryman J; Barker B; Braithwaite C; Carleton K; Hay L; Hottenstein C; Kubiak RJ; Devanarayan V
    AAPS J; 2022 Jul; 24(4):81. PubMed ID: 35821280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study.
    McCush F; Wang E; Yunis C; Schwartz P; Baltrukonis D
    AAPS J; 2023 Sep; 25(5):85. PubMed ID: 37658997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
    Ponce-Bobadilla AV; Stodtmann S; Chen MJ; Winzenborg I; Mensing S; Blaes J; Haslberger T; Laplanche L; Dreher I; Mostafa NM
    Clin Pharmacokinet; 2023 Apr; 62(4):623-634. PubMed ID: 36905528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal-to-noise ratio to assess magnitude, kinetics and impact on pharmacokinetics of the immune response to an adalimumab biosimilar.
    Guerrieri D; Horvat M; Fan J; Wang J; Lemke L; Richter OV; Poetzl J
    Bioanalysis; 2024 Jan; 16(1):33-48. PubMed ID: 38031738
    [No Abstract]   [Full Text] [Related]  

  • 5. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response.
    Starcevic Manning M; Kroenke MA; Lee SA; Harrison SE; Hoofring SA; Mytych DT; Jawa V
    Bioanalysis; 2017 Dec; 9(23):1849-1858. PubMed ID: 29020795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk.
    Bivi N; Moore T; Rodgers G; Denning H; Shockley T; Swearingen CA; Gelfanova V; Calderon B; Peterson DA; Hodsdon ME; Siegel RW; Higgs RE; Konrad RJ
    MAbs; 2019 Jul; 11(5):861-869. PubMed ID: 31099718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes.
    Shibata H; Nishimura K; Miyama C; Tada M; Suzuki T; Saito Y; Ishii-Watabe A
    J Immunol Methods; 2018 Jan; 452():73-77. PubMed ID: 28970009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope characterization of the ADA response directed against a targeted immunocytokine.
    Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
    J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
    Pederson S; Biondi DM; Allan B; Cady R; Schaeffler B; Baker B; Latham J
    Front Immunol; 2021; 12():765822. PubMed ID: 34759933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J; Schantz A; Schwegler M; Shankar G
    J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
    Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Coelho R; Tavares P; Soares J; Sousa AL; Carvalho D; Sousa P; da Silva JP; Meira T; Silva Ferreira F; Dias CC; Chowers Y; Ben-Horin S; Magro F;
    Therap Adv Gastroenterol; 2016 Nov; 9(6):781-794. PubMed ID: 27803733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance.
    Opolka-Hoffmann E; Jordan G; Otteneder M; Kieferle R; Lechmann M; Winter G; Staack RF
    MAbs; 2021; 13(1):1995929. PubMed ID: 34763611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.
    Wyant T; Yang L; Rosario M
    AAPS J; 2020 Nov; 23(1):3. PubMed ID: 33200296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the NIDS® rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics.
    Pan J; Small T; Qin D; Li S; Wang L; Chen D; Pauley C; Verch T; Kaplanski C; Bakhtiar R; Vallejo YR; Yin R
    J Pharmacol Toxicol Methods; 2011; 63(2):150-9. PubMed ID: 20868758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
    Weeraratne DK; Lofgren J; Dinnogen S; Swanson SJ; Zhong ZD
    J Immunol Methods; 2013 Oct; 396(1-2):44-55. PubMed ID: 23933325
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ubah OC; Porter AJ; Barelle CJ
    J Immunol Res; 2020; 2020():7283239. PubMed ID: 32090129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.